Core Viewpoint - The company Maipu Medical is planning to acquire 100% equity of Yijie Medical for a total consideration of 334.85 million yuan, which includes both cash and stock payments, aiming to enhance its product line and competitive edge in the neuro-interventional medical device sector [1][2][4]. Trading Information Summary - As of October 16, 2025, Maipu Medical's stock closed at 71.02 yuan, down 0.87%, with a turnover rate of 0.87% and a trading volume of 4,867 shares, amounting to a transaction value of 35.10 million yuan [1]. - On the same day, the net inflow of funds from major investors was 352,300 yuan, while retail investors experienced a net outflow of 250,350 yuan [1][4]. Company Announcement Summary - The company held its 15th meeting of the third board of directors on October 16, 2025, where it approved the draft report for the acquisition of Yijie Medical [1][3]. - The acquisition involves a total transaction price of 334.85 million yuan, with 301.06 million yuan paid in shares and 33.79 million yuan in cash. The valuation of the target company represents a 259.91% increase over its net asset value [1][2][4]. - The company plans to raise 133.58 million yuan from its actual controller, Yuan Yuyu, to support the acquisition and related projects [2][4]. Performance Commitment Summary - Yijie Medical has committed to a net profit of -19.10 million yuan in 2025, -3.16 million yuan in 2026, and positive profits of 14.87 million yuan, 33.36 million yuan, and 52.01 million yuan in the subsequent years [2]. Approval Process Summary - The transaction is subject to approval by the company's shareholders and must be reviewed by the Shenzhen Stock Exchange and registered with the China Securities Regulatory Commission. A special shareholders' meeting is scheduled for November 3, 2025, to vote on this and other resolutions [3].
股市必读：迈普医学（301033）10月16日主力资金净流入35.23万元